Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685751 | 0.87 | LMNA (0.44) | HDAC1HDAC2SMN1; SMN2ADORA3PKM | |
| SCHEMBL2684960 | 0.85 | TSHR (0.40) | HDAC1HDAC2ADORA3 | |
| SCHEMBL2686893 | 0.80 | HDAC1 (0.54) | RAB9ANPC1MEN1KMT2AHDAC1 | |
| SCHEMBL2686090 | 0.79 | NPC1 (0.49) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL2686355 | 0.78 | HDAC1 (0.54) | RAB9ANPC1KMT2AHDAC1TP53 | |
| SCHEMBL1754072 | 0.78 | HDAC1 (0.60) | RAB9AHDAC1HDAC2TP53ADORA3 | |
| SCHEMBL2685935 | 0.78 | HDAC1 (0.55) | RAB9ANPC1MEN1KMT2AHDAC1 | |
| SCHEMBL13985027 | 0.78 | ADORA3 (0.51) | HDAC1HDAC2SMN1; SMN2ADORA3 | |
| SCHEMBL1689347 | 0.76 | HDAC1 (0.55) | RAB9AHDAC1HDAC2TP53ADORA3 | |
| SCHEMBL13950308 | 0.76 | HDAC1 (0.47) | RAB9AMEN1KMT2AHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | claimed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | claimed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | claimed |
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| EP-1991226-A2 | INHIBITORS OF HISTONE DEACETYLASE | Merck & Co., Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC6 | RAB9A 4368/4885NPC1 3227/4885MEN1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.